EUVIMEDEUVIMED entdecken
Crossref

Sjögren's Disease and Cancer: Key Predictors From the Spanish Multicenter SjögrenSER ‐ TRANS Cohort

Olga Rusinovich-Lovgach iD, Zulema Plaza iD, Mónica Fernández Castro iD, Carlos Sánchez-Piedra iD, José Rosas, Victor Martínez-Taboada iD, Alejandro Olivé, Raul Menor Almagro, Beatriz Rodrígez-Lozano iD, Angel Garcia-Aparicio iD, Francisco Javier Lopez Longo, Sara Manrique-Arija iD und 9 weitere

Journal of Oral Pathology & Medicine · 2026

DOI: 10.1111/jop.70123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oral Pathology & Medicine, 2026. Verfasst von Olga Rusinovich-Lovgach und 20 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain. Hauptthemen laut MEDLINE: Neoplasms, Sjogren's Syndrome, Registries. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Sociedad Española de Reumatología.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To identify key clinical and therapeutic predictors of malignancy in a well‐characterized, multicenter Spanish cohort of patients with Sjögren's disease (SjD).

Methods

A retrospective, cross‐sectional study was conducted using data from the SjögrenSER‐TRANS registry, a national cohort of 437 SjD patients from 33 Spanish hospitals who fulfilled the 2002 AECG classification criteria. Clinical, serological, and treatment‐related variables were systematically collected. Descriptive statistics were used to summarize demographic and clinical characteristics. Bivariate analysis (chi‐squared for categorical variables and t ‐tests for continuous variables) was performed to identify associations with malignancy ( p < 0.05), followed by multivariate logistic regression to determine independent predictors.

Results

Malignancy was identified in 30 patients (6.86%), with gynecological cancers (30%) and lymphomas (23.3%) being the most common types. Independent predictors of malignancy included older age (OR 1.042, 95% CI 1.007–1.079), glandular inflammation (OR 2.888, 95% CI 1.281–6.512), and rituximab use (OR 3.959, 95% CI 1.461–10.730).

Conclusion

This study underscores the role of older age, glandular inflammation, and rituximab use as key risk factors for malignancy in SjD. However, the association with rituximab should be interpreted with caution, as indication bias cannot be ruled out. These findings emphasize the need for improved risk stratification and targeted surveillance strategies to facilitate early detection and enhance malignancy management in clinical practice. Prospective studies are warranted to refine monitoring protocols and optimize patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsSjogren's SyndromeRegistriesAdultAgedFemaleHumansMaleMiddle AgedAge FactorsCohort StudiesCross-Sectional StudiesLymphomaRetrospective StudiesRisk FactorsRituximabSpain

Substanzen

Rituximab

Autor:innen und Institutionen

  • Rheumatology Department, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.
  • Research Unit, Spanish Society of Rheumatology, Madrid, Spain.
  • Spanish Agency of Health Technology Assessment, Instituto de Salud Carlos III, Madrid, Spain.
  • Rheumatology Department, Marina Baixa de la Vila Joiosa Hospital, Alicante, Spain.
  • Rheumatology Department, Marqués de Valdecilla University Hospital, Santander, Spain.
  • Departament of Medicine y Psychiatry, University of Cantabria, Santander, Spain.

ORCID-Profile: Olga Rusinovich-Lovgach, Zulema Plaza, Mónica Fernández Castro, Carlos Sánchez-Piedra, Victor Martínez-Taboada, Beatriz Rodrígez-Lozano, Angel Garcia-Aparicio, Sara Manrique-Arija, Jesús Alberto Garcia-Vadillo, Ruth Lopez-Gonzalez, Javier Narvaez García, Carlos Galisteo Lencastre, Jorge Gonzalez-Martin, Fernando Alonso, Jose Luis Andreu

Förderung

  • Sociedad Española de Reumatología

Zitieren

APA

Rusinovich-Lovgach, O., Plaza, Z., Castro, M. F., Sánchez-Piedra, C., Rosas, J., Martínez-Taboada, V., Olivé, A., Menor Almagro, R., Rodrígez-Lozano, B., Garcia-Aparicio, A., Lopez Longo, F. J., Manrique-Arija, S., Garcia-Vadillo, J. A., Gil Barato, S., Lopez-Gonzalez, R., Narvaez García, J., Galisteo Lencastre, C., Gonzalez-Martin, J., Alonso, F., …, & SJÖGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER) (2026). Sjögren's Disease and Cancer: Key Predictors From the Spanish Multicenter SjögrenSER ‐ TRANS Cohort. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.70123

Vancouver

Rusinovich-Lovgach O, Plaza Z, Castro MF, Sánchez-Piedra C, Rosas J, Martínez-Taboada V, et al. Sjögren's Disease and Cancer: Key Predictors From the Spanish Multicenter SjögrenSER ‐ TRANS Cohort. Journal of Oral Pathology & Medicine. 2026. doi:10.1111/jop.70123

BibTeX
@article{RusinovichLovgach2026,
  author = {Rusinovich-Lovgach, Olga and Plaza, Zulema and Castro, Mónica Fernández and Sánchez-Piedra, Carlos and Rosas, José and Martínez-Taboada, Victor and Olivé, Alejandro and Menor Almagro, Raul and Rodrígez-Lozano, Beatriz and Garcia-Aparicio, Angel and Lopez Longo, Francisco Javier and Manrique-Arija, Sara and Garcia-Vadillo, Jesús Alberto and Gil Barato, Susana and Lopez-Gonzalez, Ruth and Narvaez García, Javier and Galisteo Lencastre, Carlos and Gonzalez-Martin, Jorge and Alonso, Fernando and Andreu, Jose Luis and SJÖGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER), SJÖGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER)},
  title = {Sjögren's Disease and Cancer: Key Predictors From the Spanish Multicenter SjögrenSER ‐ TRANS Cohort},
  journal = {Journal of Oral Pathology & Medicine},
  year = {2026},
  doi = {10.1111/jop.70123}
}
Kostenlos starten →